AI-powered digital healthcare company AIDOT announced that its artificial intelligence solution, Cerviray AI®, demonstrated high diagnostic performance in a clinical study for early cervical cancer screening conducted in West Bandung, Indonesia, securing its potential entry into the global screening market, particularly in low-resource countries.
The study was led by the Department of Obstetrics and Gynecology as well as the Epidemiology and Statistics teams at Universitas Padjadjaran, involving a total of 71 local women.
According to the report, Cerviray AI® showed the following performance compared with Indonesia’s national screening standard, VIA (Visual Inspection with Acetic acid):
- Specificity: 95.6%
- Negative Predictive Value (NPV): 98.5%
- Accuracy: 94.4%
- AUC: 0.811
The high NPV of 98.5% is a key indicator of the AI’s ability to safely exclude normal cases, reducing unnecessary follow-up tests and healthcare costs. This is particularly significant in low-resource settings such as Indonesia, where access to HPV testing and biopsies is limited.
The report also highlighted that Cerviray AI®’s algorithm minimizes false positives through a conservative threshold, making it well-suited for large-scale national screening programs.
In addition, when combined with expert interpretation in Expert Mode, the system demonstrated:
- Specificity: 97.1%
- Positive Predictive Value (PPV): 50.0%
- Accuracy: 95.8%
- Cohen’s Kappa (agreement with VIA): 0.550
These results show that the hybrid triage model, where AI handles initial screening and experts review only ambiguous cases, improves both predictive performance and diagnostic agreement, potentially increasing screening efficiency 2–3 times in regions with limited medical personnel.
Cervical cancer remains a major public health challenge in Indonesia, with approximately 36,000 new cases annually. While AI-based screening is expected to be in high demand, limited healthcare infrastructure and the subjective nature of VIA testing have historically resulted in low early detection rates. Cytology and HPV testing also face regional limitations, equipment accessibility issues, and high costs.
The researchers from Universitas Padjadjaran concluded that the high specificity and NPV of Cerviray AI® make it a reliable tool for community-based primary screening and provide a strong basis for integration into government-led national screening programs.
WHO’s 2030 Cervical Cancer Elimination Initiative also identifies AI-based imaging for screening as a key tool, highlighting the global relevance of AIDOT’s solution.
Jaehoon Jung, CEO of AIDOT, stated, “Cerviray AI® is an on-device AI system capable of immediate interpretation without internet or cloud access. Our clinical study in Bandung not only demonstrates strong competitiveness in large-scale screening markets across Indonesia, Vietnam, Thailand, and India but also provides real-world evidence of its superiority over domestic or Israel-based imitation products that cannot detect lesion locations. The Bandung Health Department has already voluntarily committed to an additional 900-subject clinical study, validating the AI’s performance in real-world settings. We will continue accelerating our expansion in the Southeast Asian women’s cancer screening market.”
Key features of Cerviray AI® include:
- On-device AI analysis (instant results without internet)
- First Class 3 AI medical device approved by the Korean MFDS
- 4-level lesion classification (Normal / CIN1 / CIN2,3 / Cancer)
- Detailed lesion detection boxes
- Remote expert interpretation (Expert Mode)
- New battery-replaceable device design
Source: Korea Economic TV / December 4, 2025 / Reporter Yang Jaejun
